NRXSHealthcare · Biotechnology

NRXS Stock Forecast: NeurAxis, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026

$6.77

−0.88% on the day

The 2 Wall Street analysts covering NeurAxis, Inc. hold a median 12-month price target of $11 — +62.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 58 of 100 as at 8 Oct 2026 — in the upper half.

Market cap

$85.1M

Ticker Nerd rank

58 / 100

Median analyst target

$11

Analysts covering

Revenue$1.9M+115.7% y/y

Operating income−$2.1M

Net income−$2.1M

Free cash flow−$1.0M

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

−5.6%

+14.6%

YTD

+49.1%

+116.3%

From 52W high

−23.2%

From 52W low

+193.1%

$2.31

$8.81

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

NRXS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores NeurAxis, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026

58 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum

Size

Accruals

Growth

Volatility

Issuance

Revisions

Value

Quality

Momentum (95): The shares have been drifting up relative to others.

Quality (29): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NRXS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NRXS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts

2 Buy0 Hold0 Sell

Low $9Median $11High $13

The green dot is the last close — the median target sits +62.5% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
20 Mar 2026	Craig-Hallum	Maintains	Buy	—
22 Dec 2025	Craig-Hallum	Maintains	Buy	—
16 June 2025	Craig-Hallum	Initiates	Buy	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NRXS appears on the weeks it earns a place.

Performance

NRXS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, NeurAxis, Inc. returned +116.3% against +16.2% for the S&P 500, dividends included.

NRXS vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NRXS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

NeurAxis, Inc. (NRXS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −7.1×
Price / sales: 16.0×
Price / book: 12.6×
EV / EBITDA: −10.1×

Growth & margins

Revenue growth (YoY): 115.7%
Earnings growth (YoY): 115.7%
Gross margin: 85.9%
Operating margin: −110.2%
Net margin: −144.4%

Returns & dividend

Return on equity: −139.8%
Return on assets: −56.2%
Dividend yield: 0.0%

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

NeurAxis, Inc. (NRXS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

NeurAxis, Inc. has a market value of $85.1M and an enterprise value of $77.1M.
Revenue in the twelve months to 30 June 2026: $5.3M. The latest quarter grew 115.7% year on year.
Net income over the same four quarters: −$7.7M, a −144.4% net margin.
Free cash flow in the twelve months to 30 June 2026: −$5.7M.
Shares outstanding: 12.5M.
Trailing P/E: −7.1×; forward P/E: −25.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
NeurAxis, Inc. employs 24 people — $222K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

NRXS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
NRXSNeurAxis, Inc.	$85.1M	58
TELOTelomir Pharmaceuticals, Inc.	$84.7M	28
CGTXCognition Therapeutics, Inc.	$85.1M	35
CRDFCardiff Oncology, Inc.	$81.7M	46
NMRANeumora Therapeutics, Inc.	$87.3M	30
ACRVAcrivon Therapeutics, Inc.	$80.0M	68
ICCCImmuCell Corp.	$88.2M	93

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own NeurAxis, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NRXS news & analysis

NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer

GlobeNewsWire · 29 Sept 2026positive

NeurAxis, Inc. announced the appointment of Craig Blanchard as Chief Commercial Officer on September 29, 2026. The company, which commercializes neuromodulation therapies for chronic conditions in children and adults, said the appointment positions it for the next phase of commercial growth.

Why it matters — A new Chief Commercial Officer signals NeurAxis's focus on advancing its commercial strategy and growth phase, which is relevant for investors tracking the company's development.

NeurAxis Announces Medical Coverage Policy Milestone, Expanding Access to Over 18 million additional Covered Lives

GlobeNewsWire · 16 Sept 2026positive

NeurAxis announced a medical coverage policy milestone, with a major national health insurer adding coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), expanding access to over 18 million additional covered lives.

Why it matters — Expanded insurance coverage could broaden patient access to NeurAxis's PENFS therapy, potentially supporting wider adoption of its neuromodulation treatments.

NeurAxis to Participate in the Lytham Partners Fall 2026 Investor Conference

GlobeNewsWire · 16 Sept 2026neutral

NeurAxis, Inc. announced it will participate in the Lytham Partners Fall 2026 Investor Conference, delivering a webcast presentation and hosting one-on-one investor meetings virtually on September 29-30, 2026.

Why it matters — The company's investor-conference participation increases its visibility and provides an opportunity to communicate its neuromodulation therapies to the investment community.

Neuraxis Gains Nearly 137% in a Year: What's Driving the Stock?

Zacks Investment Research · 15 Sept 2026positive

Neuraxis, Inc. shares have risen nearly 137% over the past year, driven by stronger IB-Stim volumes, broader reimbursement, and expanded VA access. However, incomplete payer coverage and ongoing cash needs remain challenges for the company.

Why it matters — An NRXS watcher would care because the report highlights the key revenue drivers supporting the stock's strong run while also flagging the reimbursement and cash challenges that could affect future performance.

NeurAxis, Inc. (NRXS) Presents at IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 Transcript

Seeking Alpha · 15 Sept 2026neutral

NeurAxis, Inc. presented at the IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026, with a transcript of the presentation made available. The presentation was hosted virtually as part of the conference's lineup.

Why it matters — A NRXS watcher would care because the company's management used the conference to publicly present its business to an investor audience, offering insight into its current positioning.

FAQ

Frequently asked questions about NRXS stock

What is the NRXS stock price forecast for 2026-2027?

The 2 Wall Street analysts covering NeurAxis, Inc. have a median 12-month price target of $11, with estimates ranging from $9 to $13. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NRXS stock a buy right now?

Of the 2 analysts covering NeurAxis, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks NeurAxis, Inc. 58 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NRXS?

As at 8 Oct 2026, NeurAxis, Inc. ranks 58 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (95 of 100).

Will NRXS stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +62.5% from the last close, and Ticker Nerd's factor model ranks NeurAxis, Inc. 58 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NRXS stock forecast for 2030?

No analyst covering NeurAxis, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NRXS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $13 over the next 12 months.

How has NRXS stock performed over the past year?

NeurAxis, Inc. returned +116.3% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does NeurAxis, Inc. do?

NeurAxis, Inc. is a medical technology company focused on neuromodulation therapies for chronic and debilitating conditions, with an emphasis on disorders of the gut-brain interaction.

What is the latest news on NRXS?

The most recent item we track (GlobeNewsWire, 29 Sept 2026): "NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer". NeurAxis, Inc. announced the appointment of Craig Blanchard as Chief Commercial Officer on September 29, 2026. The company, which commercializes neuromodulation therapies for chronic conditions in children and adults, said the appointment positions it for the next phase of commercial growth.

Company

About NeurAxis, Inc.

NeurAxis, Inc. is a medical technology company focused on neuromodulation therapies for chronic and debilitating conditions, with an emphasis on disorders of the gut-brain interaction. Its current product portfolio centers on IB-Stim, a drug-free, non-surgical device worn behind the ear and designed to deliver percutaneous electrical nerve field stimulation for patients with functional abdominal pain associated with irritable bowel syndrome, functional dyspepsia, and related nausea symptoms. The company serves pediatric and adult patients through healthcare settings such as hospitals and clinics, where its therapies are used to support symptom management in targeted gastrointestinal conditions. NeurAxis also works to commercialize evidence-based devices that address unmet needs in digestive health and related neuromodulation care. Headquartered in Carmel, Indiana, NeurAxis operates as a specialized player in the medical device market with a focus on non-invasive treatment options.

CEO Mr. Brian Carrico · 24 employees · United States · https://neuraxis.com